Cost-effectiveness of psychotherapy for personality disorders Djøra Soeteman Viersprong Institute for Studies on Personality Disorders Erasmus Medical.

Slides:



Advertisements
Similar presentations
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
Advertisements

COURAGE Economic Results of the COURAGE Trial William S. Weintraub, MD Chief of Cardiology Christiana Care Health System Professor of Medicine, Thomas.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
Richard P. Halgin Susan Krauss Whitbourne
1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Prof. dr. Jan van Busschbach Department of Medical Psychology & Psychotherapy Erasmus MC.
Visit our websites: PhD Study: Evaluation of the Efficacy of the Incredible.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
Economic evaluation of outcomes: long term primary and surrogate endpoints Dr. Giampiero Favato presented at the University Program in Health Economics.
Case Management. 2 What is Case Management? Case Management is a confidential service that is available at no cost to you if you have an illness or injury.
Depression Measures Health Disparities Collaborative 2005.
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.
Program Development for Safety Net Institutions Catherine Deamant, MD Director, Palliative Care Services Cook County Health and Hospitals System Coleman.
1 Cost-effectiveness in Personality Disorder Dr. J.J.V. Busschbach Psychotherapeutic centre ‘De Viersprong’ –PO Box AA Halsteren
The Nature of Disease.
The cost-effectiveness of providing a DAFNE follow- up intervention to predicted non-responders J Kruger 1, A Brennan 1, P Thokala 1, S Heller 2 on behalf.
Palliative Care “101“. Definition Palliative Care Specialized medical care for people with serious illnesses. It is focused on providing patients with.
The Business Case for Bidirectional Integrated Care: Mental Health and Substance Use Services in Primary Care Settings and Primary Care Services in Specialty.
EPIB-591 Screening Jean-François Boivin 29 September
The Influence of Primary Care Practice Climate on Medical Services Costs and Quality of Care Roblin DW 1, Howard DH 2, Becker ER 2, Adams EK 2, Greenfield.
Measuring Health Outcomes
Treatment for Adolescents With Depression Study (TADS)
Day Hospital versus admission for acute psychiatric disorders Dr. Simon Benson ST2 General Practice.
BACKGROUND Cost-effectiveness of Psychotherapy for Cluster C Personality Disorders and the Value of Information and Implementation Djøra I. Soeteman 1,2,
1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology.
The Effectiveness of Psychodynamic Therapy and Cognitive Behavior Therapy in the Treatment of Personality Disorders: A Meta-Analysis. By Falk Leichsenring,
Evidence-Based Journal Article Presentation [Insert your name here] [Insert your designation here] [Insert your institutional affiliation here] Department.
Cost-Effectiveness of Palliative Team Care For Patients Nearing End-Of-Life Society for Medical Decision Making 36 st Annual Meeting – Miami, Florida October.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Cost effectiveness as argument for reimbursement in prevention Jan J. v. Busschbach, Ph.D. Erasmus MC –Institute for Medical Psychology and Psychotherapy.
AcademyHealth 2007 Gender Differences in Healthcare Utilization at the End-of Life Andrea Kronman, MD MSc Boston University BIRCWH Faculty Scholar Women’s.
Outcome research 1 Outcome/ instruments selection Wei-Chu Chie Preventive Medicine.
Economic evaluation of psychotherapy for personality disorders: burden of disease and cost-effectiveness Djøra Soeteman Viersprong Institute for Studies.
1 The Economic Burden of Personality Disorders  Djøra Soeteman, Jan J.V. Busschbach, Leona Hakkaart-van Roijen, Roel Verheul  Viersprong Institute for.
THE URBAN INSTITUTE Examining Long-Term Care Episodes and Care History for Medicare Beneficiaries: A Longitudinal Analysis of Elderly Individuals with.
Costs of Neurostimulation Can We Afford The Therapy in 2020? Krishna Kumar MBBS MS FRCS(C) Member Ord. of Canada, Saskatchewan Ord. of Merit Clinical Professor.
RESCUE: Assessing Health and Economic Outcomes William C. Black, M.D. Dartmouth-Hitchcock Medical Center.
Assessing Mental Health Among Latino Consumers of Mental Health Services Susan V. Eisen, PhD, Mariana Gerena, PhD, Gayatri Ranganathan, MS, Pradipta Seal.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
11 Cost Effectiveness in Preventing Crime  Jan van Busschbach, Djøra Soeteman  Viersprong Institute for studies on Personality Disorders VISPD  Erasmus.
1 The Cost Effectiveness of Treatment of Personality Disorder  Dr. Jan J.V. Busschbach  PTC De Viersprong, Erasmus MC, Rotterdam, 
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
Prepared by: Using discrete event simulation to evaluate the cost-effectiveness of antipsychotics Pharmerit BV Marten Meesweg AV Rotterdam The.
The Use of Pharmacoeconomics and Pharmacoepidemiology in Your Local MTF P&T Process by Marv Shepherd, Ph.D. Jim Wilson, Ph.D. Center for Pharmacoeconomic.
1 Value of Information in relation to risk management  Prof. Dr. Jan J.V. Busschbach.
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
Cost-Effectiveness of Psychotherapy (for Personality Disorders) Prof. dr. Jan van Busschbach.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
Differential trends in equity of health service utilization in primary, secondary & tertiary health care levels among Thai elderly across income groups.
Why does SMC say NO We all want the most effective medicines All medicines cost money Health budgets are limited How do we choose?
Inpatient Palliative Care A hospital service at SOMC where patients can benefit from palliative care consultative services during their hospitalization.
Palliative Care with Older Adults Section 3: Policy Issues Related To Aging And Palliative Care Gunnar Almgren, PhD University of Washington, School of.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
© 2010 Jones and Bartlett Publishers, LLC. Chapter 12 Clinical Epidemiology.
Community Treatment Orders use in Assertive Outreach Dr Mohammed Al-Uzri Consultant Psychiatrist & Honorary Professor (University of Leicester)
Economics of Complementary and Integrative Medicine: Where Do We Go From Here? Patricia M. Herman, ND, PhD, RAND Corporation IM4US Boston August 8, 2014.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
Introduction Out-of-hospital cardiac arrest (OHCA) is the sudden cessation of the heart in an out of hospital setting. In the United States, the incidence.
HEALTH ECONOMICS BASICS
Kaplan–Meier curves of long-term survival in young (
Presentation transcript:

Cost-effectiveness of psychotherapy for personality disorders Djøra Soeteman Viersprong Institute for Studies on Personality Disorders Erasmus Medical Center, Rotterdam Harvard School of Public Health, Boston, MA ISSPD NYC, August 23,

SCEPTRE trial  Patient-level primary data was available from the largest existing clinical trial of psychotherapy for personality disorders (N = 924)  Dosage specified by treatment setting and duration  Cluster C PD: N = 466  Cluster B PD: N = 241 2

Cluster C PD 3

4 Different dosages  Short-term outpatientexcl.  Long-term outpatient21.4%  Short-term day hospital19.0%  Long-term day hospital23.0%  Short-term inpatient14.1%  Long-term inpatient22.5%  Short-term < = 6 months  Long-term > 6 months

Different costs Psychotherapy dosageTreatment costs (€) Long-term outpatient 10,005 Short-term day hospital 16,813 Long-term day hospital 27,648 Short-term inpatient 25,933 Long-term inpatient 49,260 5

Total costs over 5 years Psychotherapy dosage Treatment costs (€) Total costs over 5 years (€) Long-term outpatient10,005 89,936 Short-term day hospital16,813 89,411 Long-term day hospital27, ,940 Short-term inpatient25,933 91,620 Long-term inpatient49, ,946 6

Just costs?  Economics is more than just costs…  Effects are equally important: –Cost-effectiveness  Are the effects worth the additional costs? –What if the more expensive treatment is more effective? –What are the costs per recovered patient? 7

8 Definition “recovered patient”  Clinically significant change: (Jacobson and Truax, 1991) –Recovered: statistically reliable  + ends up within normal limits –Improved: statistically reliable , but ends still dysfunctional –Unchanged: no statistically reliable  –Relapsed or deteriorated: statistically reliable  in the opposite direction  General Symptom Index (BSI/SCL-90)

Effect 9 Psychotherapy dosage% recovered after 12 months Long-term outpatient 19% Short-term day hospital 26% Long-term day hospital 37% Short-term inpatient 61% Long-term inpatient 41%

Costs per recovered patient year 10 Psychotherapy dosage% recovered after 12 months Costs (€) Long-term outpatient19% 64,735 Short-term day hospital26% 46,131 Long-term day hospital37% 45,442 Short-term inpatient61% 32,837 Long-term inpatient41% 57,285

Is that a lot?  How do we know if € x,- per recovered patient year concerns a ‘cost-effective’ treatment strategy?  Compare it with other interventions –E.g., compared to lung transplantation or breast cancer screening  Generic outcome measure required in order to compare different illnesses –Survival –Quality of life 11

 Life years x quality of life index score  Quality of life index score –1.0 = perfect health –0.0 = death  Example –Loss of eyesight –Quality of life index = 0.5 –Life years = 80 –0.5 x 80 = 40 QALYs 12 Quality Adjusted Life Years (QALY) 12

Effect over 5 years Psychotherapy dosageQALYs Long-term outpatient 3.30 Short-term day hospital 3.44 Long-term day hospital 3.49 Short-term inpatient 3.57 Long-term inpatient

Costs per QALY Psychotherapy dosage QALYsCosts per QALY (€) Long-term outpatient ,239 Short-term day hospital ,027 Long-term day hospital ,353 Short-term inpatient ,674 Long-term inpatient ,350 14

Interested in both costs and effect Less effectiveMore effective Low costs (savings) High costs Good Better Superb! Forget it! Difficult… 15

Sensitivity analysis Less effectiveMore effective Low costs (savings) High costs Superb! Forget it! Difficult… 16 Good Better

Cost-effectiveness plane 17 Good Better

Acceptability curve 18

Cost-effectiveness of different dosages of psychotherapy for cluster C PD Psychotherapy dosageCosts per QALY (threshold value €0 – €16,570) Costs per QALY (> €16,570) Long-term outpatient Short-term day hospital 1 st choice Long-term day hospital Short-term inpatient 1 st choice Long-term inpatient 19

Cost-effectiveness of different dosages of psychotherapy for cluster C PD Psychotherapy dosage Costs per QALY (threshold value €0 – €16,570) Costs per QALY (> €16,570) Costs per QALY (threshold value of €40,000) Long-term outpt Short-term day h 1 st choice Long-term day h Short-term inpt 1 st choice Long-term inpt 20

Cluster B PD 21

Acceptability curve 22

Cost-effectiveness of different modalities of psychotherapy for cluster B PD Modality of psychotherapy Costs per QALY (threshold value €0 – €56,325) Costs per QALY (> €56,325) Outpatient 1 st choice Day hospital 1 st choice Inpatient 23

Cost-effectiveness of different modalities of psychotherapy for cluster B PD Modality of psychotherapy Costs per QALY (threshold value €0 – €56,325) Costs per QALY (> €56,325) Costs per QALY (threshold value of €40,000) Outpatient 1 st choice Day hospital 1 st choice Inpatient 24

Conclusion  Cost-effective treatment strategies are:  Cluster C PD: –Short-term inpatient psychotherapy (first choice) –Short-term day hospital psychotherapy  Sub-optimal treatment options are: –Long-term day hospital and long-term inpatient  Cluster B PD: –Outpatient psychotherapy (first choice) –Day hospital psychotherapy  Sub-optimal treatment option is: –Inpatient psychotherapy 25